Clinical trial NCT06285539: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Official title: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Behcet's Disease
Idiopathic Inflammatory Myopathies
IgG4-related Disease
Keywords: JAK-inhibition
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
Collaborators: name: Alfasigma S.p.A.
name: ReumaNederland
name: Autoimmune Research and Collaboration Hub
First posted: 2024-02-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A 26-week multicenter, open-label, uncontrolled, non-randomized, non-blinded proof-of-concept, two-stage phase 2 study
Primary purpose: TREATMENT

Brief summary: Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.


Eligibility criteria: Inclusion Criteria:

* Age 18 years of older
* One of the following rare IMIDs:

  * Diagnosis of Behçet's disease without refractory life, organ or sight-threatening symptoms with active disease, defined as a BDCAF \>2 (new BDCAF) or \>15 (old BDCAF) or with active disease, based on clinical grounds (e.g. the need to start new or additional medication
  * Diagnosis of idiopathic inflammatory myopathy, according to diagnostic criteria:

Dermatomyositis: Dermatomyositis Classification Criteria according to the European Neuromuscular Centre guidelines 201852 or anti-synthetase syndrome: Anti- synthetase syndrome Classification Criteria according to the European Neuromuscular Centre guidelines 200353, both with active disease, defined as a CDASI score of ≥5 or abnormal levels of at least 1 of the following enzymes: creatine kinase (≥ 4× upper limit of normal \[ULN\]), aldolase (≥4 × ULN), lactate dehydrogenase (LDH ≥4 × ULN), aspartate transaminase (AST ≥4 × ULN), alanine aminotransferase (ALT ≥4 × ULN) or a MRI within the last 3 months indicative of active inflammation (e.g. edema signal pattern in affected proximal muscles) or active disease based on clinical grounds, e.g. the need to start new or additional medication

* Diagnosis of IgG4-related disease, according to 2019 ACR/EULAR guidelines, with active disease, defined as: IgG4-related disease responder index \>10 or active disease based on clinical grounds, e.g. the need to start new or additional medication

  * Refractory disease, defined as symptomatic disease that persists despite a 12-week trial of glucocorticoid therapy as well as lack of response to at least one other immunosuppressive agent such as methotrexate (MTX), mycophenolate mofetil (MMF), azathioprine (AZA) or rituximab or intolerance to standard-of-care treatment, as defined by the treating physician.
  * No evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (TB) as defined by all of the following: both a negative QuantiFERON-TB Gold (QFT-G) In-Tube test and a Mantoux tuberculin skin test performed at or within 3 months prior to screening and no signs suggestive of active TB infection as determined (and documented) by a qualified radiologist or pulmonologist as per local standard of care on a chest radiograph and no history of either untreated or inadequately treated latent or active TB infection.

Exclusion Criteria:

* Age \<18 years
* Age ≥65 years
* Life expectancy less than 6 months
* Juvenile DM, myositis overlapping with other autoimmune diseases, immune mediated necrotizing myopathy (IMNM), inclusion-body myositis or cancer-associated myositis
* End-stage IIM wherein muscle weakness is most likely due to muscle damage, rather than myositis disease activity
* Increased risk of major cardiovascular problems
* Current smoker or smoked for a long time in the past
* Pregnancy or lactation
* Previous use of other JAK inhibitors
* Use of any investigational drug within one month prior to screening or within five half-lives of the investigational agent, whichever is longer.
* Human Immunodeficiency Virus (HIV) infection
* Presence of an active infection or viral hepatitis type B or C
* History of shingles or recurrent herpes simplex infection
* Concomitant malignancies or previous malignancies within the last five years (with exception of adequately treated basal or squamous cell carcinoma of the skin)
* Increased risk of cancer
* Kidney injury with estimated glomerular filtration rate \<15mL/min/1.73m2
* Liver failure Child Pugh C
* Absolute neutrophil count \<1\*109
* Absolute leukocyte count \<0.5\*109
* Hemoglobin \<5mmol/L - Inability to comply with study and/or follow-up procedures
* Known recent substance abuse (drugs or alcohol).
* Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.
* Previous non-adherence to immunosuppressants
* Hypersensitivity to the active substance or to any of the excipients
* Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

Primary outcomes:
measure: EQ-5D-5L
timeFrame: 26 weeks
measure: Disease activity in Behcet's patients
timeFrame: 26 weeks
measure: Disease activity in myositis patients
timeFrame: 26 weeks
measure: Disease activity in IgG4-RD patients
timeFrame: 26 weeks
Secondary outcomes:
measure: Corticosteroid toxicity
timeFrame: 26 weeks
measure: Corticosteroid dosage
timeFrame: 26 weeks
measure: VAS score of pain
timeFrame: 26 weeks
measure: Fatigue
timeFrame: 26 weeks
measure: Treatment-related adverse events
timeFrame: 26 weeks
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Amsterdam UMC
city: Den Haag
country: Netherlands
facility: Hagaziekenhuis
city: Heerlen
country: Netherlands
facility: Zuyderland Medical Center
city: Nijmegen
country: Netherlands
facility: Radboud university medical center
city: Rotterdam
country: Netherlands
facility: Erasmus MC
city: Utrecht
country: Netherlands
facility: University Medical Center
Study officials:
affiliation: UMC Utrecht
name: Jaap M van Laar, Prof. dr.
role: PRINCIPAL_INVESTIGATOR
References: